

Housekeeping

- Please use the **Q&A** forum to send a message or question to the board. If you prefer to ask your question anonymously, start typing your message and a tickbox will appear to enable your message to be submitted anonymously.
- Please use the **Chat** forum for any technical or logistical problems, and send these queries to the panellists.
- There will be a series of polls throughout the AGM to record your votes. Voting is anonymous.
- The meeting is being recorded, as is the requirement of our society regulations.
- We record a list of the meeting attendees and outcomes of the voting, as is the requirement of our society regulations. We will need to send detailed information of our AGM to the Amtsgericht Mannheim (Registergericht).

ESGCT Annual General Meeting

16 September 2020

Virtual AGM

Zoom -

Agenda


1. Opening and welcome
2. Confirmation of the agenda
3. Approval of the Minutes of the AGM of 22 October 2019
4. Year 2020: Overview
5. ESGCT Board: Confirmation and mandate for prolonging term of Executive Board until annual meeting 2021
6. Report of the Treasurer: 2019 accounts
7. Discharge of the Executive Board and formal approval of the 2019 accounts
8. Report of the President
9. AOB

Agenda

3. Approval of the minutes of the AGM of 22 October 2019

4. ESGCT 2020: Overview

EUROPEAN SOCIETY OF
GENE & CELL THERAPY



ESGCT 28th Annual Congress

in collaboration with BSGCT
Edinburgh International
Conference Center

Edinburgh
19-22 January
2021



EUROPEAN
SOCIETY OF
GENE & CELL
THERAPY

British
Society
for
Gene &
Cell
Therapy

ESGCT SPRING SCHOOL 2021

Athens, Greece, 17-19 March

A comprehensive course for Master and PhD Students, free of charge for the first 50 students. The course will be held in a first-class hotel, with a first-class dinner. The course will be held in a first-class hotel, with a first-class dinner. The course will be held in a first-class hotel, with a first-class dinner.

Many opportunities to network with European leaders in gene therapy

- Pre-event workshops



EUROPEAN SOCIETY OF
GENE & CELL THERAPY



www.esgct.eu



27 May 2020 |

Current insights on the origin of SARS-CoV2

Dong-Yan JIN, The University of Hong Kong



03 June 2020 |

The COVID-19 Pandemic: Images from a "SPELL" on America

Daniel Lucey, O'Neill Institute for National and Global Health Law, Washington DC



10 June 2020 |

Novel vaccine strategies targeting SARS-CoV2

Ami Patel, The Wistar Institute, Philadelphia, PA



17 June 2020 |

SARS-CoV2 – spotlight on cell entry

Stefan Pöhlmann, Deutsches Primatenzentrum, Göttingen



e-Seminars (COVID-19)

- 4 presentations
- 156 live viewers
- 603 post-live views

e-Schools


- 15 presentations streamed weekly since 6th May (including break in August)
- 1646 total live viewers
- 5533 total post-live views (as of 10/09/20)
- Most viewed presentations
 - Hildegard Büning (06/05): Gene Therapy – From Concept to Proof (1430 total views)
 - Els Verhoeyen (20/05): How to teach enveloped vectors about cell entry targeting (931 total views)
 - Hildegard Büning (03/06): AAV vectors – to teach an old virus new tricks (792 total views).

e-Schools speakers



Viewer Demographics



- Data taken from YouTube Analytics on 10/09/20.



YouTube Analytics provides some limited audience data, including the top countries where viewers are based. (Only data from the top countries is provided. Views from other locations is unknown).


Viewer Demographics

- Data taken from YouTube Analytics on 10/09/20.



Survey Responses

- A small number of responses have been received to an audience survey (18 responses). The limited data indicates the following:



Survey Responses

- **Satisfaction results**

- E-School topics covered: 100% Excellent or Good
- E-School speaker presentations: 100% Excellent or Good
- E-Seminar topics covered: 90% Excellent or Good
- E-Seminar speaker presentations: 90% Excellent or Good
- Streaming platform (YouTube): 94% Excellent or Good
- Q&A via YouTube LiveChat: 81% Excellent or Good.

Survey Responses

- **Should online presentations, such as the e-School and e-Seminars series, become part of ESGCT's permanent programme of activities?**
 - 100% responded Yes.
- **Would you still attend an in-person congress or event in the future if the presentations from that event were also available to watch online?**
 - Yes – 67%
 - No – 6%
 - Not sure – 28%.

5. ESGCT Board: Confirmation and mandate for prolonging term of executive board until annual meeting 2021

Board prolongation



Due to the cancellation of the Edinburgh congress the election of the board will be postponed to the next congress in Brussels 2021. We need to vote for the existing board to remain in their post until the upcoming congress.

Executive Board

- Hildegard Büning: President
- Juan Bueren: President Elect
- Axel Schambach: Treasurer
- Alberto Auricchio: General Secretary

Confirmation of the posts of the above mentioned board members

Board

- Alessandro Aiuti
- Claire Booth
- Gloria Gonzalez Aseguinolaza
- Vincenzo Cerullo
- Zoltan Ivics
- Giuliana Ferrari

Confirmation of the posts of the above mentioned board members

6. Report of the Treasurer: 2019 accounts

Cost of postponing the Spring School

Cost of Sales		in EURO
Event Insurance	HISCOX event insurance	€ 545,90
Invited Speaker / Board	Board travel (after partial refunds)	€ 2.131,17
Marketing & Advertising	Banner @ Barcelona	€ 43,60
Planning Meeting	Site visit	€ 629,58
Total Cost of Sales		<u>€ 3.350,26</u>



Cost of postponing the Annual congress

Accommodation	Speaker hotel	€ 2.267,20	Trying to transfer to next congress
Event Insurance	HISCOX insurance	€ 8.219,16	Trying to transfer to next congress
Marketing & Advertising	Promo at Barcelona, BSGCT Sheffield	€ 776,51	
Planning Meeting	Site visits and expenses	€ 2.184,88	
	Branding design	€ 1.000,00	
Venue	Venue including cancellation fee	€ 145.798,60	
Total Cost of Sales		<u>€ 159.245,34</u>	

Profit and Loss - cash basis

For the year ended 31 December 2019

Turnover

Grants	17,515.31
Journal Contribution	4,369.93
Membership	124,367.15
Registration Fee	1,168,700.37
Sales	700,919.09
Total Turnover	2,015,871.85

Cost of Sales

Event costs (congress(es) and spring school(s))	1,255,324.97
Card Processing Fees	27,043.68
Fundraising & Sponsor Management	175,375.67
Profit share	273,246.03
Total Cost of Sales	1,730,990.35

Gross Profit	284,881.50
---------------------	-------------------

Profit and Loss - cash basis

For the year ended 31 December 2019

Administrative Costs

Association Management	27,358.42
Accountancy fees	5,353.21
Awards	12,012.27
Bank Fees	3,960.09
Credit Card Fees	132.63
General Expenses	416.90
Postage, Freight & Courier	38.60
Total Administrative Costs	49,272.12
Operating Profit	235,609.38

Accounts 2019 – all in € EURO

	31/12/2019	To date
ESGCT Cash in bank	1.087.817,00 €	1.044.871,47 €
Cashflow account	367.817,00 €	
Safety account	720.000,00 €	
<i>Money that will come out in the coming months</i>		
SETGYC profit share		80.000,00 €
Edinburgh Sponsorships		117.000,00 €
Running costs		200.000,00 €
Other expenses due		25.000,00 €
Estimate end Year End 2020/2021		622.871,47 €

7. Discharge of the Executive Board and formal approval of the 2019 accounts

8. Report of the President

ESGCT SPRING SCHOOL 2019

Naples, Italy, 3-5 April

An intensive three-day training course for PhD students and early career researchers new to gene and cell therapy

- The opportunity to network with Europe's current and future leaders in the field
- Support for early career researchers
- Debates
- Workshops: Public engagement | How to publish a paper | Presentation skills

150 spaces only | free registration for students



BARCELONA 2019

EUROPEAN SOCIETY OF
GENE & CELL THERAPY



RECORD NUMBERS

1907 registrations

75 sponsors

85 exhibitors

700 abstracts

THANK YOU





Student support

In Barcelona for the first time, students who had submitted abstracts accepted for presentation, received complimentary registration fee:

INVESTMENT: €50,250

We also increased the number of **travel grants awarded**

- ESGCT x 19 DG-GT x 2
- SETGYC x 3 BSGCT x 2
- SFTCG x 3

Registration stats

by country – top 15

United States	456
Spain	261
United Kingdom	228
Germany	178
France	164
Italy	110
South Korea	48
Russian Federation	52
Switzerland	46
Japan	41
Belgium	32
The Netherlands	31
Finland	22
China	19
Austria	16

Abstracts stats

700 abstracts	INV	OR	POS
	104	50	650

Auditor of books / transactions

- ESGCT member
- Check incoming and outgoing transactions are justified
- Per calendar year Jan – Dec
- To start for 2020, report due AGM 2021
- Candidate for this position Manuel Grez

ESGCT Committees



1. [Alumni Advisory Committee](#)
(CHAIRS Robin Ali, Nathalie Cartier)
2. [ECR / Student Engagement & Education](#)
(CHAIRS Hildegard Büning, Gloria Gonzalez-Aseguinolaza)
3. [Government relations & regulatory, national societies, membership](#)
(CHAIRS Alessandro Aiuti, Hildegard Büning)
4. [Public engagement & communications](#)
(CHAIRS Vincenzo Cerullo, Zoltan Ivics)
5. [Nominations & awards, programme & abstracts](#)
(CHAIRS Alberto Auricchio, Claire Booth)
6. [Ethics, clinical trial & commercialisation](#)
(CHAIRS Axel Schambach, Giuliana Ferrari)

Future ESGCT meetings and spring school

- 19 to 22 October, 2021 – Square conference center, Brussels
- 13 -15 April 2022 - Spring school in Athens
- 10 to 14 October 2022 – EICC, Edinburgh

You had confirmed your presence in Edinburgh
We hope to see you in Brussels – Thank you for support

EUROPEAN SOCIETY OF
GENE & CELL THERAPY



Diamond



European Federation of Pharmaceutical
Industries and Associations



Platinum



Biopharma
Excellence



Gold

cevec

charles river

Human
Gene Therapy

Mary Ann Liebert, Inc. publishers



REPLIGEN
INSPIRING ADVANCES IN BIOPROCESSING

EUROPEAN SOCIETY OF
GENE & CELL THERAPY



Silver

BIO-RAD

BIOCAIR[®]

MOVING SCIENCE FORWARD



cellex.
Cell Professionals



Eurogentec



FinVector

GYROS PROTEIN
Technologies



KCT
Kuopio Center
for Gene and Cell Therapy



Lonza

NHS
Blood and Transplant

Polyplus⁺
transfection™
THE DELIVERY EXPERTS

QPS
CUSTOM-BUILT RESEARCH™



sartorius stedim
biotech



STILLA



TaKaRa